La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cartesian Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cartesian Therapeutics..

Cartesian Therapeutics (NASDAQ:RNAC) Azioni, Catena delle Opzioni

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

Benchmark analyst Bruce Jackson reiterates VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Hold.

News

Reiteration

Analyst Ratings

VNRX

Benchmark Reiterates Hold on VolitionRX

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Speculative Buy and maintains $3 price target.

Price Target

UNCY

Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target

Truist Securities analyst Jamie Cook maintains AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Buy and raises the price target from $119 to $129.

Truist Securities Maintains Buy on AECOM, Raises Price Target to $129

Truist Securities analyst Tobey Sommer maintains ICF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) with a Hold and lowers the price target from $180 to $140.

ICFI

Truist Securities Maintains Hold on ICF International, Lowers Price Target to $140

Wells Fargo analyst Michael Turrin maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Overweight and raises the price target from $340 to $350.

ADSK

Wells Fargo Maintains Overweight on Autodesk, Raises Price Target to $350

Earnings

MOGU

MOGU H1 2025 EPS RMB(2.76) Up From RMB(4.11) YoY; Revenue RMB61.9M Down From RMB83.3M YoY

Truist Securities analyst Tobey Sommer maintains Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) with a Hold and lowers the price target from $185 to $155.

Truist Securities Maintains Hold on Booz Allen Hamilton, Lowers Price Target to $155

Wells Fargo analyst Aaron Rakers maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Equal-Weight and raises the price target from $135 to $140.

NTAP

Wells Fargo Maintains Equal-Weight on NetApp, Raises Price Target to $140

Truist Securities analyst Tobey Sommer maintains Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) with a Buy and lowers the price target from $205 to $185.

LDOS

Truist Securities Maintains Buy on Leidos Holdings, Lowers Price Target to $185

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues its climb toward $100,000, but traders are adopting cautious approaches to prepare <a href="https://www.benzinga.com/money/bitcoin-price-prediction">for potential corrections</a>.
What Happened: Crypto chart analyst Ali Martinez observed a sell signal on Bitcoin's 4-hour chart, indicating a possible brief correction to $97,085. 
However, a candlestick close above $100,470 could invalidate this bearish setup and push BTC to $102,656 or $104,343.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The TD Sequential presents a sell signal on the <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> 4-hour chart, anticipating a brief correction to $97,085! A candlestick close above $100,470 will invalidate the bearish formation and potentially push <a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> to $102,656 or $104,343. <a href="https://t.co/WiKQTGYNmJ">pic.twitter.com/WiKQTGYNmJ</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1859873122389983779?ref_src=twsrc%5Etfw">November 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In another tweet, Martinez shared his strategy for protecting capital during Bitcoin&#8217;s next bear market. Predicting a peak between $173,779 and $461,862 by October 2025, he suggests:
<ul>
<li>Selling 25% of holdings between $173,000 &#8211; $200,000.</li>
<li>Selling 30% between $200,000 &#8211; $300,000.</li>
<li>Selling another 30% between $300,000 &#8211; $400,000.</li>
<li>Selling the final 15% if BTC surpasses $400,000.</li>
</ul>
Additionally, Martinez advises traders to employ a 15%-20% trailing stop-loss after Bitcoin reaches $170,000. He underscores a strict deadline: "If Oct 2025 hits, sell—no matter what."
Also Read: <a href="https://www.benzinga.com/general/education/24/11/42125880/if-you-bought-1-worth-of-bitcoin-at-launch-heres-how-much-youd-have-today-2">If You Bought $1 Worth Of Bitcoin At Launch, Here&#8217;s How Much You&#8217;d Have Today</a>
Why It Matters: Martinez <a href="https://x.com/ali_charts/status/1859909759945850904">noted</a> that over 65,000 BTC, worth $6.37 billion, have been withdrawn from exchanges in the past 96 hours.
IntoTheBlock data shows large transaction volume increasing by 47.5% and daily active addresses grew by 27.2%. Transactions greater than $100,000 are up from 13,321 to 18,859 in a single day. Exchanges netflows are down by 4.5%.
Lookonchain data <a href="https://x.com/lookonchain/status/1859671734951252362">highlighted</a> the ten Bitcoin ETFs saw a netflow of 8,585, worth $842.7 million, in one day. BlackRock inflows increased by 6,643 BTC, worth $652.08 million, bringing its total to 481,270 BTC.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42116183/michael-saylor-predicted-bitcoin-to-hit-13-million-if-it-happens-it-will-entail-massive-hyperinflation-analyst-warns">Michael Saylor Predicted Bitcoin To Hit $13 Million — If It Happens, It Will Entail &#8216;Massive Hyperinflation,&#8217; Analyst Warns</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Zeroes In On $100,000, But This Indicator Signals One More Brief Correction

Truist Securities analyst Tobey Sommer maintains Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) with a Buy and lowers the price target from $130 to $110.

Truist Securities Maintains Buy on Parsons, Lowers Price Target to $110

Wells Fargo analyst Andrew Nowinski maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Overweight and raises the price target from $100 to $135.

ESTC

Wells Fargo Maintains Overweight on Elastic, Raises Price Target to $135

Wells Fargo analyst Chris Carey maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Overweight and raises the price target from $188 to $190.

Wells Fargo Maintains Overweight on Procter & Gamble, Raises Price Target to $190

Truist Securities analyst Tobey Sommer maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Buy and lowers the price target from $650 to $550.

CACI

Truist Securities Maintains Buy on CACI International, Lowers Price Target to $550

Wells Fargo analyst Ike Boruchow maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Overweight and raises the price target from $28 to $30.

Wells Fargo Maintains Overweight on Gap, Raises Price Target to $30

Oppenheimer analyst Kristen Owen maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Outperform and raises the price target from $448 to $477.

Oppenheimer Maintains Outperform on Deere, Raises Price Target to $477

Cantor Fitzgerald analyst Kristen Kluska reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight and maintains $11 price target.

CDXS

Cantor Fitzgerald Reiterates Overweight on Codexis, Maintains $11 Price Target

WIIM

LGTY

Logility Supply Chain Solutions shares are trading lower after the company reported worse-than-expected Q2 revenue results and issued FY25 revenue guidance below estimates.

Oppenheimer analyst Scott Schneeberger maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Outperform and raises the price target from $712 to $722.

INTU

Oppenheimer Maintains Outperform on Intuit, Raises Price Target to $722

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Overweight.

KROS

Cantor Fitzgerald Reiterates Overweight on Keros Therapeutics

Analyst Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) and keeping the price target at $41.00. Gi...

Promising Phase IIb Results and Sustained Efficacy Bolster Buy Rating for Cartesian Therapeutics

Mizuho Securities analyst Uy Ear has maintained their bullish stance on RNAC stock, giving a Buy rating today. Uy Ear has given his Buy rating due ...

Buy Rating for Cartesian Therapeutics Supported by Promising Descartes-08 Phase 2b Results and Upcoming Catalysts

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today. The company's shares closed last...

TD Cowen Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today. The company's shares opened toda...

TD Cowen Remains a Buy on Cartesian Therapeutics (RNAC)

Needham analyst Gil Blum has maintained their bullish stance on RNAC stock, giving a Buy rating today. Gil Blum has given his Buy rating due to a c...

Positive Outlook for Cartesian Therapeutics: Buy Rating Driven by Promising Study Results and Strategic Initiatives

In a report released today, Matthew Biegler from Oppenheimer maintained a Hold rating on Cartesian Therapeutics (RNAC – Research Report). The compa...

Cartesian Therapeutics (RNAC) Receives a Hold from Oppenheimer

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cartesian Therapeutics (RNAC – Research Report), Allogene Therape...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)

Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presente...

Cartesian Therapeutics Reports Q3 2024 Financial Results

Cartesian Therapeutics: Uncertainty Remains

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Cartesian Therapeutics Receives Buy Rating After Promising Phase 2b Trial Results and Strategic Advancements

ALLO

ARGX

MRNA

RNAC

Health Care

Press Releases

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Comments

Cartesian Therapeutics

Cartesian Therapeutics (RNAC) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO